http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Agile Therapeutics (AGRX) Prices 15M Share Offering at $3/Sh
-
Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock
-
Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock
-
Agile Therapeutics (AGRX) to Offer Common Stock
-
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
-
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
-
Agile Therapeutics (AGRX) Announces FDA Approval of Twirla Transdermal System
-
FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg
-
FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg
-
Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting
-
Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting
-
Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress
-
Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress
-
Agile Therapeutics (AGRX) Announces $7.8 Million Private Placement of Common Stock
-
Agile Therapeutics Announces $7.8 Million Private Placement
-
Agile Therapeutics Announces $7.8 Million Private Placement
-
Agile Therapeutics (AGRX) Announces Twirla Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane
-
Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
-
Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
-
Agile Therapeutics (AGRX) Provides Regulatory Update and Reiterates Cash Guidance
-
Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance
-
Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance
-
Agile Therapeutics (AGRX) Meets With FDA on Comparative Wear Study of Twirla and Xulane
-
Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®
-
Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®
-
Agile Therapeutics (AGRX) Highlights Additional Analyses of AG200-15 (Twirla) Phase 3 SECURE Study Results
-
Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP)
-
Agile Therapeutics (AGRX) Completes Formal Dispute Resolution Process with the FDA
-
Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA
-
Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA
-
Agile Therapeutics (AGRX) Reports Initial Formal Dispute Resolution Request Denial from FDA for Twirla
-
FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request
-
FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request
-
Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance
-
Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance
-
Agile Therapeutics (AGRX) Provides Twirla Update; Says FDA Has Significant Concerns Regarding the Adhesion of Twirla
-
Agile Therapeutics (AGRX) Announces Regulatory Update on Twirla; FDA Continues to have Significant Concerns
-
Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy
-
Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy
-
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
-
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
-
Agile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy
-
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
-
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
-
Agile Therapeutics (AGRX) Announces Additional Phase 3 SECURE Trial Results for Twirla
-
Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017
-
Agile Therapeutics to Host First Analyst Day on October 10, 2017
-
Agile Therapeutics (AGRX) to Present Additional Phase 3 Data on AG200-15
-
Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting
-
Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

